PTC Therapeutics receives Japanese approval for Sephience in full-spectrum PKU

Japan approves Sephience for PKU across all ages. Find out what this means for PTC Therapeutics’ global rare disease expansion strategy.

Japan approves Sephience for PKU across all ages. Find out what this means for PTC Therapeutics’ global rare disease expansion strategy.